12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $400000 | -$130M | 0.0% | -35851.3% | -$79M | — | $125M |
| 2024 | $38M | -$77M | 0.0% | -114.7% | -$33M | — | $213M |
| 2023 | $26M | -$220M | 0.0% | -332.3% | -$51M | — | $77M |
| 2022 | $111M | $35M | 0.0% | 13.1% | -$33M | — | $106M |
| 2021 | $85M | -$26M | 0.0% | -5.4% | -$61M | — | $114M |
| 2020 | $17M | -$69M | 0.0% | -342.4% | $34M | — | $139M |
| 2019 | $7M | -$55M | 0.0% | -785.6% | -$51M | — | $90M |
| 2018 | $903000 | -$65M | 0.0% | -7200.7% | -$60M | — | $37M |
| 2017 | $207000 | -$65M | 0.0% | -30813.5% | -$53M | — | $71M |
| 2016 | $8M | -$36M | 0.0% | -428.9% | -$20M | — | $59M |
| 2015 | — | -$25M | — | — | -$24M | — | $32M |
| 2014 | — | -$13M | — | — | — | — | $17M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$39M | — | — | -$22M | — | $119M |
| Dec '25 | $0 | -$93M | — | — | -$18M | — | $125M |
| Sep '25 | $0 | -$36M | — | — | -$17M | — | $143M |
| Jun '25 | $0 | $16M | — | — | -$20M | — | $160M |
| Mar '25 | $400000 | -$18M | 0.0% | -5472.3% | -$24M | — | $180M |
| Dec '24 | -$836000 | -$10M | 0.0% | 3197.5% | -$8M | — | $213M |
| Sep '24 | $0 | -$24M | — | — | $7M | — | $219M |
| Jun '24 | $33M | $14M | 0.0% | 41.3% | -$16M | — | $87M |
| Mar '24 | $6M | -$57M | 0.0% | -228.6% | -$17M | — | $103M |
| Dec '23 | $8M | -$178M | 0.0% | -439.5% | -$23M | — | $77M |
| Sep '23 | $7M | -$9M | 0.0% | -199.4% | -$9M | — | $80M |
| Jun '23 | $5M | -$11M | 0.0% | -355.1% | -$10M | — | $112M |
| Mar '23 | $6M | -$22M | 0.0% | -309.5% | -$9M | — | $126M |
| Dec '22 | $17M | $6M | 0.0% | -50.6% | -$12M | — | $106M |
| Sep '22 | $21M | -$8M | 0.0% | -7.7% | $4M | — | $113M |
| Jun '22 | $39M | $9M | 0.0% | 35.3% | -$12M | — | $138M |
| Mar '22 | $34M | $29M | 0.0% | 31.7% | -$12M | — | $113M |
| Dec '21 | $30M | $12M | 0.0% | 13.6% | -$32M | — | $114M |
| Sep '21 | $24M | -$18M | 0.0% | -8.1% | -$11M | — | $115M |
| Jun '21 | $20M | $5M | 0.0% | 2.3% | -$7M | — | $126M |
How the market has priced RNAC against its own fundamentals since 2023-11 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cartesian Therapeutics, Inc.'s revenue has declined 52.5% per year. These are computed facts, not advice.
As of FY2025, Cartesian Therapeutics, Inc. reported — of total debt against $125M of cash.
In FY2025, gross margin was —, operating margin -35851.3%, and net margin -32575.5%.
As of Jun '26, Cartesian Therapeutics, Inc. traded at a price-to-earnings ratio of about 1.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.